Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Net Income: 2013-2024

Historic Net Income for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to -$105.5 million.

  • Zevra Therapeutics' Net Income rose 98.36% to -$544,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 139.40%. This contributed to the annual value of -$105.5 million for FY2024, which is 129.13% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Net Income of -$105.5 million as of FY2024, which was down 129.13% from -$46.0 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Net Income ranged from a high of -$8.6 million in FY2021 and a low of -$105.5 million during FY2024.
  • For the 3-year period, Zevra Therapeutics' Net Income averaged around -$59.4 million, with its median value being -$46.0 million (2023).
  • Per our database at Business Quant, Zevra Therapeutics' Net Income soared by 47.94% in 2020 and then plummeted by 212.94% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Net Income (Yearly) stood at -$12.8 million in 2020, then surged by 32.99% to -$8.6 million in 2021, then slumped by 212.94% to -$26.8 million in 2022, then crashed by 72.00% to -$46.0 million in 2023, then plummeted by 129.13% to -$105.5 million in 2024.